Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelmnews2022-05-03T18:00:36+00:00May 3rd, 2022|The New York Times|
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trialsnews2022-04-07T23:32:59+00:00April 7th, 2022|The New York Times|
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drugnews2022-04-06T18:43:00+00:00April 6th, 2022|The New York Times|
F.D.A. Rushed a Drug for Preterm Births. Did It Put Speed Over Science?news2022-03-25T15:15:07+00:00March 25th, 2022|The New York Times|
Senate Confirms Califf as F.D.A. Chief in Tight Votenews2022-02-15T18:47:59+00:00February 15th, 2022|The New York Times|
Medicare Proposes to Sharply Limit Coverage of the Alzheimer’s Drug Aduhelmnews2022-01-12T01:22:10+00:00January 12th, 2022|The New York Times|
Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decisionnews2021-12-31T21:39:22+00:00December 31st, 2021|The New York Times|
How to Cope With Medicare’s Rising Costsnews2021-12-22T10:00:19+00:00December 22nd, 2021|The New York Times|
How to Cope With Medicare’s Rising Costsnews2021-12-22T10:00:19+00:00December 22nd, 2021|The New York Times|
Biogen Slashes Price of Alzheimer’s Drug Aduhelm, as It Faces Obstaclesnews2021-12-21T02:08:14+00:00December 21st, 2021|The New York Times|
